PHA support group leader volunteers take on many roles in the pulmonary hypertension (PH) community. Many are living with PH -- others are caregivers or health care professionals -- in addition to being constituents, advocates, friends, mentors and champions of the PH community. Support group leader Stephanie Bachelder recently reached out as a PH
Seven new videos — four in English and three in Spanish — are now live on PHA Classroom. We invite you to view these newly-released “Quick Clips” to get answers to some of the most frequently asked questions that PHA receives from the PH community. PH-treating health care professionals provide answers to questions on
The Patient Advocate Foundation (PAF) has reopened a co-pay assistance fund for qualifying patients with pulmonary hypertension. PAF is accepting applications for new and renewal patients. The maximum award level is $9,000 per year. Patient must be insured by Medicare, Medicaid, or Military Benefits and insurance must cover the medication for which patient seeks assistance. Learn
Although the past decades of discovery and research have yielded drugs that improve prognosis and quality of life, the long-term survival rates for people living with PAH is still unacceptably low. A recent editorial offers thoughts on assessing risk for people living with this disease. by Phyllis Hanlon, Contributing Writer In the past decades of
The 6th World Symposium on Pulmonary Hypertension will take place in Nice, France from Feb. 27 to March 1, 2018. This symposium, held every 5 years, is a time for global leaders in PH to review the major advances in the disease, analyze the evidence in studying and treating PH, and evaluate gaps of
PHA Accreditation Program Assures Access to Specialized Care for Thousands With Often-Misdiagnosed Deadly Lung Disease
Silver Spring, MD (February 15, 2018) – A national accreditation program launched by the Pulmonary Hypertension Association (PHA) assures that more than 12,000 people with a life-threatening lung disease are getting care from clinicians who specialize in their often-misdiagnosed condition. Pulmonary hypertension (PH), also known as high blood pressure of the lungs, affects adults
Seeking Financial Assistance Because of Caring Voice Developments? Previous CVC Clients Should Make That Clear When Contacting Manufacturers.
In January, the Department of Health and Humans Services informed companies that manufacture PH medications that they would be permitted to provide one year of free medication to some individuals who received assistance from the Caring Voice Coalition as of Nov. 28, 2017. To be eligible, a PH patient must have health insurance through a
Study looks at a theory that adding immunoadsorption, or the process of filtering out antibodies from the blood, in addition to other PH therapies may help improve outcomes for people with idiopathic pulmonary arterial hypertension. by Phyllis Hanlon, Contributing Writer People with idiopathic pulmonary arterial hypertension (IPAH), a type of WHO Group 1 PH (PAH,
PHA was recently made aware of a national shortage of the diluent used for mixing some PH medications. The shortage is a result of product manufactures who have been affected by the 2017 hurricane season. The specialty pharmacies that deliver PH medications are working to monitor available supplies and purchase as much inventory as possible.
by Phyllis Hanlon, Contributing Writer WHO Group 1 PH (PAH, pulmonary arterial hypertension) is a progressive and chronic disease. There currently is no cure. In PAH, the arteries in the lungs become narrow, thickened or stiff, which causes high blood pressure in the lungs. The disease can present in several forms, one of which